Astrazeneca PLC ($AZN) Stock Forecast: Up 5.1% Today

What is Astrazeneca PLC?

AstraZeneca (AZN) Market: AstraZeneca (AZN) had a bullish movement today, driven by positive Q4 earnings and future growth prospects.

Why is Astrazeneca PLC going up?

AZN stock is up 5.1% on Feb 11, 2026 18:43

• AstraZeneca reported strong Q4 earnings, with a 9% product sales growth and a 23.4% operating margin, leading to an upgrade to a Buy rating with a 25% medium-term upside.
• The company's focus on oncology and pipeline developments, aiming for $80 billion in revenues by 2030, has instilled confidence in investors.
• Despite falling slightly short of performance expectations in Q4, the overall positive trajectory of the company's revenue and profit, along with its strategic investments in emerging therapeutic areas like obesity, have contributed to the bullish market movement.
• The company's successful cancer treatments and upcoming Phase III clinical trial readouts further bolstered investor optimism, driving the stock price higher.

AZN Price Chart

AZN Technical Analysis

AZN News

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy (AZN)

AstraZeneca reported strong 2025 results with 9% product sales growth and a 23.4% operating margin, along with a dividend increase. The company aims for $80 billion in revenues by 2030, driven by oncology and pipeline developments. Despite upcoming patent expirations for key drugs, new pipeline assets and AI innovations are expected to sustain growth, leading to an upgrade of AZN to Buy with an anticipated 25% medium-term upside.

https://seekingalpha.com/article/4868333-astrazeneca-q4-earnings-analysis-ticks-the-boxes-upgrading-to-buy

Sustained By Cancer Success, AstraZeneca Is Still Sizing Up Obesity Opportunity

AstraZeneca is currently riding a wave of success thanks to its oncology portfolio but is also actively exploring opportunities within the obesity market. The company anticipates a busy year with no fewer than 20 Phase III clinical trial readouts expected. This strategic focus highlights both continued investment in its established strengths and an eye towards emerging therapeutic areas.

https://insights.citeline.com/scrip/business/earnings/sustained-by-cancer-success-astrazeneca-is-still-sizing-up-obesity-opportunity-EKGCEL5EEBA6ZAZMYB4FXUAJVE/

Astrazeneca: Q4 Earnings Snapshot

Astrazeneca (AZN) reported fourth-quarter earnings of $2.33 billion, or 75 cents per share, which adjusted to $1.06 per share. These results, along with revenue of $15.5 billion, fell short of Wall Street expectations. For the full year, the company posted a profit of $10.23 billion on revenue of $58.74 billion, with its stock climbing 2.5% year-to-date and 31% over the past 12 months.

https://www.kens5.com/article/syndication/associatedpress/astrazeneca-q4-earnings-snapshot/616-bda9b05c-7576-4483-8d17-6f0db738a38f

Astrazeneca: Q4 Earnings Snapshot

Astrazeneca PLC reported fourth-quarter earnings of $2.33 billion, or 75 cents per share, which adjusted for non-recurring costs, amounted to $1.06 per share. These results, along with revenue of $15.5 billion, missed Wall Street expectations. For the full year, the company posted a profit of $10.23 billion on revenue of $58.74 billion, with its shares having climbed 2.5% year-to-date and 31% over the last 12 months.

https://www.kare11.com/article/syndication/associatedpress/astrazeneca-q4-earnings-snapshot/616-bda9b05c-7576-4483-8d17-6f0db738a38f

Earnings Flash (AZN.L) AstraZeneca PLC Posts FY25 EPS $6.54

AstraZeneca PLC has reported its fiscal year 2025 earnings per share (EPS) of $6.54. This release is part of a broader set of announcements from the company, including its full-year revenue of $58.74 billion, and reflects general growth with positive analyst ratings from various financial institutions.

https://www.marketscreener.com/news/earnings-flash-azn-l-astrazeneca-plc-posts-fy25-eps-6-54-ce7e5adfdc8bf426

Trending Today

Gold ($XAU) Commodity Forecast: Down 6.3% Today

Silver ($XAG) Commodity Forecast: Down 11.8% Today

Applovin Corporation ($APP) Stock Forecast: Down 9.2% Today

Amphenol Corporation ($APH) Stock Forecast: Down 5.6% Today

Alibaba Group Holding Limited ($BABA) Stock Forecast: Down 12.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 6.9% Today

Tesla Inc. ($TSLA) Stock Forecast: Down 5.3% Today

Ethereum ($ETH) Crypto Forecast: Down 5.0% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Astrazeneca PLC Price History

28.09.2025 - AZN Stock was down 0.8%

• AstraZeneca's stock experienced a strong bearish movement recently.
• The decrease in short interest by 28.0% indicates reduced speculation on the stock's decline, potentially signaling a lack of confidence in its short-term performance.
• Investors might be reacting to concerns about the company's upcoming earnings or potential setbacks in its drug development pipeline, leading to the negative market sentiment.
• The focus on another company's oncology drugs and their growth prospects could have diverted investor attention away from AstraZeneca, contributing to the bearish movement in its stock price.

30.04.2025 - AZN Stock was up 3.2%

• AstraZeneca's stock saw a notable increase following the approval of Imfinzi by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for use in muscle-invasive bladder cancer. This approval is a significant milestone for the company, enhancing investor confidence in its oncology portfolio.
• The regulatory decision was supported by promising results from the phase III NIAGARA study, showcasing the effectiveness and safety of Imfinzi in combination therapy. The release of this positive data likely contributed to the surge in investor optimism and the subsequent rise in stock price.
• The market's positive response reflects confidence in AstraZeneca's ability to deliver innovative treatments to patients and solidifies its position in the pharmaceutical industry. This regulatory approval is expected to attract more investor attention to AZN stock.

11.01.2026 - AZN Stock was up 5.1%

• AstraZeneca reported strong Q4 earnings, with a 9% product sales growth and a 23.4% operating margin, leading to an upgrade to a Buy rating with a 25% medium-term upside.
• The company's focus on oncology and pipeline developments, aiming for $80 billion in revenues by 2030, has instilled confidence in investors.
• Despite falling slightly short of performance expectations in Q4, the overall positive trajectory of the company's revenue and profit, along with its strategic investments in emerging therapeutic areas like obesity, have contributed to the bullish market movement.
• The company's successful cancer treatments and upcoming Phase III clinical trial readouts further bolstered investor optimism, driving the stock price higher.

03.06.2025 - AZN Stock was down 1.3%

• Despite the positive performance of AstraZeneca in the latest trading session, the overall market sentiment towards the stock was bearish, resulting in a notable decrease in its value.
• The decline in AstraZeneca's stock price could be attributed to investors' concerns about the company's long-term growth prospects, as indicated by the downward trend over the past month and year.
• The information about Pfizer's strong late-stage pipeline and potential for long-term growth may have inadvertently shifted investor attention away from AstraZeneca, impacting its stock performance negatively.
• Investors may be reevaluating AstraZeneca's price-to-earnings ratio in light of the recent market movements and industry developments, leading to a more cautious outlook on the stock.

09.03.2025 - AZN Stock was down 7.7%

• The EU approval for expanded use of two separate cancer drugs by Astrazeneca did not seem to have a positive impact on the stock price, as it closed lower.
• Despite the positive news of Enhertu reducing the risk of disease progression in breast cancer patients and the expanded label for Imfinzi in lung cancer, investors may have been expecting even more significant developments.
• The market's reaction could indicate that investors were possibly concerned about other factors such as competition in the cancer drug market or overall market conditions, leading to the bearish movement in Astrazeneca's stock.

05.00.2026 - AZN Stock was down 1.3%

• Institutional investors are increasingly acquiring shares of AstraZeneca PLC, signaling confidence in the company's future and financial performance.
• AstraZeneca recently posted positive quarterly earnings, with analysts giving it a "Moderate Buy" rating; however, the stock saw a bearish movement, likely due to profit-taking or shifting market sentiment.
• Various wealth management firms have collectively increased their stock holdings in AstraZeneca, indicating a positive long-term outlook despite the recent bearish trend.
• The stock's downturn today may be influenced by industry trends or broader macroeconomic factors affecting the pharmaceutical sector.

06.01.2025 - AZN Stock was up 5.9%

• AstraZeneca reported strong Q4 earnings with revenue exceeding expectations, particularly driven by higher sales in oncology and respiratory drugs.
• Despite facing potential fines in China, the company's positive financial outlook for FY25, projecting revenue growth and EPS growth, boosted investor confidence.
• The multiple class action lawsuits against AstraZeneca seem to have had minimal impact on the stock price, indicating that investors are more focused on the company's operational performance and future prospects.
• Overall, the bullish movement in AstraZeneca's stock today can be attributed to the robust Q4 earnings report and optimistic guidance for the future, outweighing any legal challenges the company currently faces.

02.01.2026 - AZN Stock was down 0.4%

• Reduction of stake by Federated Hermes Inc. by 23.9% might have indicated a lack of confidence in the company's future performance.
• Despite strong quarterly earnings and strategic moves, the bearish movement could be linked to profit-taking by investors following a positive period.
• Transition to a harmonized global listing on the NYSE and the EU recommendation for Imfinzi may have initially uplifted investor sentiment but the market may have reacted adversely due to various factors.
• Shift from Nasdaq to the NYSE and positive news on Imfinzi could have initially excited investors, but some may have taken the opportunity to sell and secure profits, leading to the bearish movement.

04.03.2025 - AZN Stock was down 5.1%

• The partnership with OncoHelix to provide liquid biopsy testing for prostate cancer patients could be seen as a positive development, but the market may have already priced in this event.
• The FDA approval for Imfinzi's expanded use in bladder cancer indicates the company's commitment to advancing its oncology portfolio, which should have been a positive catalyst.
• Despite the positive developments, the market might have reacted bearishly due to concerns about competition in the oncology space or broader market conditions impacting pharmaceutical stocks.
• Investors may be uncertain about the potential market impact of the FDA approvals on AstraZeneca's revenue and profitability, leading to a cautious outlook and the bearish movement in the stock price.

04.03.2025 - AZN Stock was down 7.7%

• AstraZeneca received multiple approvals for its flagship cancer drugs and expanded indications for Imfinzi in bladder cancer, showcasing the company's commitment to developing cutting-edge treatments.
• Despite the positive developments on drug approvals and partnerships, the market reaction suggests that investors may have been expecting even more significant progress or revenue projections.
• The milestone payment owed to Daiichi Sankyo and the partnership with OncoHelix could indicate increased expenses or investments in research and development, potentially affecting short-term profitability and stock performance.
• There is uncertainty about the market's next move, which may have contributed to the bearish trend as investors exercise caution regarding the company's future growth prospects in the competitive pharmaceutical industry.

06.00.2026 - AZN Stock was up 5.3%

• Institutional investors like My Personal CFO LLC, Moody Lynn & Lieberson LLC, and Smith Salley Wealth Management have been acquiring significant stakes in AstraZeneca, signaling confidence in the company's future prospects.
• AstraZeneca's recent strong quarterly earnings results, with EPS of $1.19 and revenue of $15.19 billion, have impressed analysts and investors alike, leading to a positive market sentiment towards the stock.
• The company's focus on R&D spend, robust pipeline, and global presence has positioned it as a strong contender for long-term growth, attracting investors looking for stability and diversified growth opportunities.
• The overall positive outlook for AstraZeneca, coupled with increased institutional investments and strong financial performance, has likely contributed to the bullish movement in the stock today.

01.09.2025 - AZN Stock was up 9.3%

• AstraZeneca's recommendation for a Harmonized Listing Structure across multiple stock exchanges may have boosted investor confidence and attracted more shareholders, contributing to the bullish movement.
• The launch of AstraZeneca Direct, offering discounted prices for prescribed medications through an online platform, could have been perceived positively by investors, driving up the stock price.
• The FDA's priority review for AstraZeneca and Daiichi's Enhertu in breast cancer, based on promising phase III data, likely added to the positive sentiment surrounding AstraZeneca's stock.
• Despite a recent decline in stock price, the overall market movement today suggests that investors are focusing more on the company's strategic initiatives and potential growth opportunities, leading to the bullish trend in AstraZeneca's stock.